SCHEMBL2083546

SCHEMBL2083546

Cc1ncccc1C(C)(C)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.39
ALDH1A1 P00352 1/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
NR3C2 P08235 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPK1 P28482 1/20 0.34
CYP2A6 P11509 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
COMT P21964 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2080649 0.84 CYP19A1 (0.45) CYP3A4KDM4EMAPK1SMN1; SMN2
SCHEMBL799554 0.77 CA2 (0.41) ALDH1A1KDM4ECYP2A6TSHR
SCHEMBL14438762 0.76 CYP2A6 (0.39) CYP3A4ALDH1A1ESR1ESR2CYP2A6
SCHEMBL2199266 0.76 ALDH1A1 (0.54) CYP3A4ALDH1A1ESR1ESR2NR3C2
SCHEMBL2085967 0.75 ALDH1A1 (0.46) CYP3A4ALDH1A1ESR1ESR2KDM4E
SCHEMBL2084716 0.75 KDM4E (0.37) CYP3A4ALDH1A1ESR1ESR2NR3C2
SCHEMBL2083721 0.74 P2RX7 (0.39) ALDH1A1KDM4ECYP2A6SMN1; SMN2TSHR
SCHEMBL18963844 0.74 SLC22A12 (0.37)
SCHEMBL2696931 0.73 ALDH1A1 (0.46) CYP3A4ALDH1A1ESR1ESR2NR3C2
SCHEMBL9421204 0.73 ESR1 (0.46) CYP3A4ALDH1A1ESR1ESR2NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 CYP3A4 3372/4885ALDH1A1 357/4885ESR1 896/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 CYP3A4 3377/4885ALDH1A1 424/4885ESR1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.